Literature DB >> 12436442

Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy.

Takahiro Yamasaki1, Fumie Kurokawa, Hitoshi Shirahashi, Noriyoshi Kusano, Kouji Hironaka, Kiwamu Okita.   

Abstract

BACKGROUND: The therapeutic efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is limited by the small volume of coagulation necrosis obtained at each activation of the RF system and the sometimes irregular burn shape due to the proximity of large vessels that have a cooling effect. To improve the efficacy of RFA, the authors designed RFA with balloon occlusion of the hepatic artery (balloon-occluded RFA). In this study, we investigated the efficacy of balloon-occluded RFA and compared the coagulation diameters obtained with balloon-occluded RFA and standard RFA.
METHODS: We retrospectively studied 31 patients with 42 HCC lesions measuring less than 4 cm in the greatest dimension. We performed balloon-occluded RFA for 12 patients (n = 15 nodules) and standard RFA for 19 patients (n = 27 nodules). Initial therapeutic efficacy was evaluated with dynamic computed tomography scan performed 2 weeks after one treatment.
RESULTS: There were no significant differences in the ablation conditions such as the frequency of a fully expanded electrode, the number of needle insertions, application cycles, or treatment times between the two groups. However, the greatest dimension of the area coagulated by balloon-occluded RFA was significantly larger (greatest long-axis dimension, 36.6 +/- 3.8 mm; greatest short-axis dimension, 30.1 +/- 6.0 mm; n = 15 lesions) than that coagulated by standard RFA (greatest long-axis dimension, 26.7 +/- 6.4 mm; greatest short-axis dimension, 23.1 +/- 5.0 mm; n = 27 lesions; greatest long-axis dimension, P < 0.001; greatest short-axis dimension, P < 0.001).
CONCLUSIONS: Balloon-occluded RFA is superior to standard RFA for the treatment of many hepatocellular lesions, especially when larger volumes of coagulation are required. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10966

Entities:  

Mesh:

Year:  2002        PMID: 12436442     DOI: 10.1002/cncr.10966

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  42 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  Radiofrequency ablation in a previously irradiated liver.

Authors:  Marc A Friedman; Rosemary Altemus; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

Review 3.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 4.  Radiofrequency thermal ablation of liver tumors.

Authors:  Elisabetta Buscarini; Agostino Savoia; Gianfranco Brambilla; Fernanda Menozzi; Luigi Reduzzi; Deike Strobel; Johannes Hänsler; Luigi Buscarini; Luigi Gaiti; Alessandro Zambelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

Review 5.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

6.  Quantitative magnetic resonance temperature mapping for real-time monitoring of radiofrequency ablation of the liver: an ex vivo study.

Authors:  Olivier Seror; Matthieu Lepetit-Coiffé; Bruno Quesson; Hervé Trillaud; Chrit T W Moonen
Journal:  Eur Radiol       Date:  2006-04-11       Impact factor: 5.315

7.  Emerging local ablation techniques.

Authors:  Michael J Stone; Bradford J Wood
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

8.  Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study.

Authors:  Jeong Han Kim; Hyung Joon Yim; Kwang Gyun Lee; Seung Young Kim; Eun Suk Jung; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Jong Eun Yeon; Hong Sik Lee; Soon Ho Um; Kwan Soo Byun; Ho Sang Ryu
Journal:  Hepatol Int       Date:  2011-07-05       Impact factor: 6.047

Review 9.  Radiofrequency ablation of cancer.

Authors:  Marc Friedman; Igor Mikityansky; Anthony Kam; Steven K Libutti; McClellan M Walther; Ziv Neeman; Julia K Locklin; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2004-06-03       Impact factor: 2.740

10.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma.

Authors:  Jianfeng Wang; Yaoping Shi; Zhibin Bai; Yonggang Li; Longhua Qiu; Guy Johnson; Feng Zhang; Xiaoming Yang
Journal:  Int J Hyperthermia       Date:  2016-09-20       Impact factor: 3.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.